CN1621047A - Medicine for treating hysteromyoma - Google Patents
Medicine for treating hysteromyoma Download PDFInfo
- Publication number
- CN1621047A CN1621047A CNA200310105219XA CN200310105219A CN1621047A CN 1621047 A CN1621047 A CN 1621047A CN A200310105219X A CNA200310105219X A CN A200310105219XA CN 200310105219 A CN200310105219 A CN 200310105219A CN 1621047 A CN1621047 A CN 1621047A
- Authority
- CN
- China
- Prior art keywords
- radix
- medicine
- heavy
- treatment
- sargassum
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 28
- 206010046798 Uterine leiomyoma Diseases 0.000 title claims abstract description 13
- 229940079593 drug Drugs 0.000 title description 11
- 235000003143 Panax notoginseng Nutrition 0.000 claims description 10
- 241000180649 Panax notoginseng Species 0.000 claims description 10
- 241000628997 Flos Species 0.000 claims description 9
- 241000195474 Sargassum Species 0.000 claims description 9
- 239000008517 radix Trichosanthis Substances 0.000 claims description 9
- 239000007941 film coated tablet Substances 0.000 claims description 6
- 239000003826 tablet Substances 0.000 claims description 4
- 239000000284 extract Substances 0.000 claims description 2
- 238000010298 pulverizing process Methods 0.000 claims description 2
- 239000008280 blood Substances 0.000 abstract description 17
- 210000004369 blood Anatomy 0.000 abstract description 17
- 230000000694 effects Effects 0.000 abstract description 9
- 238000002360 preparation method Methods 0.000 abstract description 2
- 241000512259 Ascophyllum nodosum Species 0.000 abstract 1
- 241000913745 Spatholobus Species 0.000 abstract 1
- 241000245665 Taraxacum Species 0.000 abstract 1
- 235000005187 Taraxacum officinale ssp. officinale Nutrition 0.000 abstract 1
- 241000218989 Trichosanthes Species 0.000 abstract 1
- 210000003056 antler Anatomy 0.000 abstract 1
- 238000000605 extraction Methods 0.000 abstract 1
- 239000000463 material Substances 0.000 abstract 1
- 230000001737 promoting effect Effects 0.000 description 7
- 230000017531 blood circulation Effects 0.000 description 5
- 210000004291 uterus Anatomy 0.000 description 5
- 210000001015 abdomen Anatomy 0.000 description 4
- 208000011580 syndromic disease Diseases 0.000 description 4
- 241000721047 Danaus plexippus Species 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 206010061692 Benign muscle neoplasm Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 201000004458 Myoma Diseases 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 239000008956 guizhi-fuling Substances 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 230000003285 pharmacodynamic effect Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 235000019640 taste Nutrition 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 206010027514 Metrorrhagia Diseases 0.000 description 1
- 208000029312 Muscular tumor Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 208000036029 Uterine contractions during pregnancy Diseases 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 229940121657 clinical drug Drugs 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 231100001252 long-term toxicity Toxicity 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 210000004914 menses Anatomy 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000009495 sugar coating Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 206010042772 syncope Diseases 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention is one kind of Chinese medicine preparation for treating hysteromyoma due to energy stagnation and blood stasis in high curative effect. The Chinese medicine is prepared with antler, dandelion, kelp, trichosanthes root, spatholobus stem and other 10 kinds of Chinese medicinal materials, and through crushing, extraction and tabletting.
Description
Technical field:
The present invention is the Chinese medicine preparation that belongs to treatment syndrome of qi stagnation and blood stasis hysteromyoma.
Background technology:
At present the Chinese patent medicine of treatment syndrome of qi stagnation and blood stasis hysteromyoma seldom, clinical efficacy is all undesirable.Unique way has only excision, but the patient is relatively more painful, and applicable object has certain limitation again, and has the some cases postoperative easily to recur.We show that by results of study such as market survey, clinical contrast observation's test, pharmacodynamics tests like products such as commercially available GUIZHI FULING JIAONANG, GONGLIUQING capsule, GONGLIUNING PIAN are used for the treatment of uterus intermural myoma and Subserous myoma has certain curative effect.Subjective symptoms makes moderate progress after patient's medication, as: the recovery that menstruation has is normal, and lower abdomen dull pain or distending pain of the breast alleviate, and metrorrhagia is alleviated.But detect and gynecologial examination tumor body is not seen obviously yet and dwindled through B ultrasonic, the Evolution of Tongue Inspection of TCM pulse condition does not still have change, illustrates that above medicine treatment hysteromyoma therapeutic effect is all undesirable.
Summary of the invention:
The present invention just provides a kind of medicine that the syndrome of qi stagnation and blood stasis hysteromyoma is had good therapeutic effect.
The object of the present invention is achieved like this: by percentage to the quality, be exactly with Cornu Cervi 8.9～8.902%, Herba Taraxaci 5.93～5.935%, Thallus Laminariae (Thallus Eckloniae) 23.145～23.15%, Radix Trichosanthis 2.37～2.374%, Caulis Spatholobi 5.93～5.935%, Radix Notoginseng 5.93～5.935%, Radix Paeoniae Rubra 1.78%, Sargassum 11.57～11.573%, Radix Rhapontici 3.56～3.561%, the Radix Aucklandiae 4.748～4.75%, Radix Scrophulariae 5.93～5.935%, Cortex Moutan 8.309～8.31%, Spica Prunellae 5.93～5.935%, Fructus Forsythiae 2.37～2.374%, Flos Carthami 3.56～3.561% is through pulverizing, extract, compacting forms.
The beneficial effect of the invention:
1. prescription rationally demonstrates fully the differentiation of tcm principle:
The present invention selects Cornu Cervi for use, and the merit of promoting the circulation of blood is arranged.Tang. numerous in the Meng " Treatise on Dietetic Therapy " is promptly controlled " surplus blood is desired the dead not to the utmost among the uterus " with its single.The Radix Aucklandiae " dispersing liver-energy ", " controlling all gas of trusted subordinate " is so " book on Chinese herbal medicine justice " claims: " lump in the abdomen, this is necessary medicine ".Among two medicines, Cornu Cervi specially department is gone into the uterus blood circulation promoting and blood stasis dispelling, and the Radix Aucklandiae is specially managed the mechanism of qi of lower abdomen imbalance, closes and is usefulness, becomes blood circulation promoting and blood stasis dispelling altogether, manages the effect of the stagnation of QI.The pathogenesis that hits, thereby be monarch drug in the side altogether.Use blood circulation promoting and blood stasis dispelling such as Radix Notoginseng, Caulis Spatholobi, Flos Carthami, Radix Paeoniae Rubra, Cortex Moutan, removing obstruction for relieving pain in the side in addition; With row irritabilities such as Herba Taraxaci, Spica Prunellae, Fructus Forsythiae, Radix Trichosanthis, separate stagnation of liver-QI, the stagnant gas of row, the crux of loosing.More than the auxilliary monarch drug blood-activating and qi-promoting eliminating stagnation in nine flavor footpaths, Yu Fangzhong all takes charge of the duty of ministerial drug.
Qi depression to blood stasis, the uterus muscular tumor becomes, is engaged in headed by Thallus Laminariae (Thallus Eckloniae), Sargassum, Radix Scrophulariae, Radix Rhapontici, hard masses softening and resolving when assistant again, be making supporting movement to cut off enemy of all medicines of the monarch and his subjects altogether, all lift the labor of adjuvant drug.
Full side ten five tastes, using medicines of both cold and hot natures simultaneously stresses blood circulation promoting and blood stasis dispelling with the resistance of the promoting the circulation of blood knot stasis of blood; And with the eliminating stagnation of regulating the flow of vital energy with orderly and clearly mechanism of qi, it is capable to promote blood; The eliminating mass removing mass with softening the hard mass of holding concurrently is dispeled the lower abdomen enclosed mass.So menses mixes well, the disease piece dissipates, and the merit of fainting can become.
2. prove through the pharmacodynamic study result: medicine of the present invention (it is capable to ask for an interview adnexa 1 page 1 3-4) has blood circulation promoting and blood stasis dispelling, promotes the effect that blood stasis dissipates; Has the effect of adjusting body inner estrogen level; Have the promotion uterine contraction, get rid of the effect of uterus foreign body; Effect with anti-inflammation detumescence inhibition proliferative lesion.Its effect all is better than commercially available " GONGLIUNING PIAN, GONGLIUQING capsule and GUIZHI FULING JIAONANG " (asking for an interview the 6th page of 6～8 row of adnexa 1).
3. show through the animal acute toxicity test data: medicine oral administration administration acute toxicity of the present invention very little (asking for an interview adnexa 2 page 21 row reciprocal); The result shows through long-term toxicity test for animals: can think that the long-term continuous use toxicity of RUPIPIAN is very low, infer clinical application safety better (it is capable to ask for an interview the 15th page of 2-3 reciprocal of adnexa 3).
4. prove through the Preliminary Clinical Observation result of the test: Drug therapy syndrome of qi stagnation and blood stasis hysteromyoma obvious effective rate of the present invention (contain and cure number) reaches 65.1%, total effective rate reaches 93%, most patients promptly has obvious curative effects after course of treatment of medication, can receive satisfactory therapeutic effects two courses of treatment, has no adverse reaction.Fully can be as the medicine (except the need operative treatment person) of hysteromyoma.
5. the finished product physicochemical property of making, assays etc. all meet these product item of Pharmacopoeia of the People's Republic of China version in 2000 pertinent regulations down, and State Food and Drug Administration also ratifies to have issued " clinical drug research official written reply " (asking for an interview adnexa 4).
This medicine is to adopt the common process method to produce.Narrate the production process that this medicine is produced below:
More than ten five tastes, Radix Scrophulariae, Radix Notoginseng, Cornu Cervi pulverize separately become fine powder; All the other Herba Taraxacis etc. 12 flavor decocts with water secondary, and 3 hours for the first time, 2 hours for the second time, collecting decoction filtered, and is concentrated in right amount, is mixed with above-mentioned fine powder and an amount of adjuvant, makes granule, and drying, tabletting, sugar coating or film-coat are promptly.
Embodiment 1:
Cornu Cervi 300g, Herba Taraxaci 200g, Thallus Laminariae (Thallus Eckloniae) 780g, Radix Trichosanthis 80g, Caulis Spatholobi 200g, Radix Notoginseng 200g, Radix Paeoniae Rubra 60g, Sargassum 390g, Radix Rhapontici 120g, Radix Aucklandiae 160g, Radix Scrophulariae 200g, Cortex Moutan 280g, Spica Prunellae 200g, Fructus Forsythiae 80g, Flos Carthami 120g
Make 3370 (coated tablet, the heavy 0.32g of every plain sheet altogether; Film coated tablets, every heavy 0.34g).
Embodiment 2:
Cornu Cervi 89.02g, Herba Taraxaci 59.35g, Thallus Laminariae (Thallus Eckloniae) 231.45g, Radix Trichosanthis 23.74g, Caulis Spatholobi 59.35g, Radix Notoginseng 59.35g, Radix Paeoniae Rubra 17.8g, Sargassum 115.73g, Radix Rhapontici 35.6g, Radix Aucklandiae 47.48g, Radix Scrophulariae 59.35g, Cortex Moutan 83.09g, Spica Prunellae 59.35g, Fructus Forsythiae 23.74g, Flos Carthami 35.6g
Make 1000 (coated tablet, the heavy 0.32g of every plain sheet altogether; Film coated tablets, every heavy 0.34g).
Embodiment 3:
Cornu Cervi 89.02g, Herba Taraxaci 59.35g, Thallus Laminariae (Thallus Eckloniae) 231.45g, Radix Trichosanthis 23.74g, Caulis Spatholobi 59.35g, Radix Notoginseng 59.35g, Radix Paeoniae Rubra 17.8g, Sargassum 115.73g, Radix Rhapontici 35.6g, Radix Aucklandiae 47.48g, Radix Scrophulariae 59.35g, Cortex Moutan 83.09g, Spica Prunellae 59.35g, Fructus Forsythiae 23.74g, Flos Carthami 35.6g
Make 500 (Film coated tablets, every heavy 0.67g) altogether.
Claims (4)
1. medicine for the treatment of hysteromyoma, it is characterized in that: by percentage to the quality, be exactly with Cornu Cervi 8.9～8.902%, Herba Taraxaci 5.93～5.935%, Thallus Laminariae (Thallus Eckloniae) 23.145～23.15%, Radix Trichosanthis 2.37～2.374%, Caulis Spatholobi 5.93～5.935%, Radix Notoginseng 5.93～5.935%, Radix Paeoniae Rubra 1.78%, Sargassum 11.57～11.573%, Radix Rhapontici 3.56～3.561%, the Radix Aucklandiae 4.748～4.75%, Radix Scrophulariae 5.93～5.935%, Cortex Moutan 8.309～8.31%, Spica Prunellae 5.93～5.935%, Fructus Forsythiae 2.37～2.374%, Flos Carthami 3.56～3.561% is through pulverizing, extract, compacting forms.
2. a kind of medicine for the treatment of hysteromyoma according to claim 1 is characterized in that: Cornu Cervi 300g, Herba Taraxaci 200g, Thallus Laminariae (Thallus Eckloniae) 780g, Radix Trichosanthis 80g, Caulis Spatholobi 200g, Radix Notoginseng 200g, Radix Paeoniae Rubra 60g, Sargassum 390g, Radix Rhapontici 120g, Radix Aucklandiae 160g, Radix Scrophulariae 200g, Cortex Moutan 280g, Spica Prunellae 200g, Fructus Forsythiae 80g, Flos Carthami 120g
Make 3370 altogether, coated tablet, the heavy 0.32g of every plain sheet; Film coated tablets, every heavy 0.34g.
3. a kind of medicine for the treatment of hysteromyoma according to claim 1 is characterized in that: Cornu Cervi 89.02g, Herba Taraxaci 59.35g, Thallus Laminariae (Thallus Eckloniae) 231.45g, Radix Trichosanthis 23.74g, Caulis Spatholobi 59.35g, Radix Notoginseng 59.35g, Radix Paeoniae Rubra 17.8g, Sargassum 115.73g, Radix Rhapontici 35.6g, Radix Aucklandiae 47.48g, Radix Scrophulariae 59.35g, Cortex Moutan 83.09g, Spica Prunellae 59.35g, Fructus Forsythiae 23.74g, Flos Carthami 35.6g
Make 1000 altogether, coated tablet, the heavy 0.32g of every plain sheet; Film coated tablets, every heavy 0.34g.
4. a kind of medicine for the treatment of hysteromyoma according to claim 1 is characterized in that: Cornu Cervi 89.02g, Herba Taraxaci 59.35g, Thallus Laminariae (Thallus Eckloniae) 231.45g, Radix Trichosanthis 23.74g, Caulis Spatholobi 59.35g, Radix Notoginseng 59.35g, Radix Paeoniae Rubra 17.8g, Sargassum 115.73g, Radix Rhapontici 35.6g, Radix Aucklandiae 47.48g, Radix Scrophulariae 59.35g, Cortex Moutan 83.09g, Spica Prunellae 59.35g, Fructus Forsythiae 23.74g, Flos Carthami 35.6g
Make 500 altogether, Film coated tablets, every heavy 0.67g.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB200310105219XA CN1255137C (en) | 2003-11-28 | 2003-11-28 | Medicine for treating hysteromyoma |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB200310105219XA CN1255137C (en) | 2003-11-28 | 2003-11-28 | Medicine for treating hysteromyoma |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1621047A true CN1621047A (en) | 2005-06-01 |
| CN1255137C CN1255137C (en) | 2006-05-10 |
Family
ID=34757217
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB200310105219XA Expired - Lifetime CN1255137C (en) | 2003-11-28 | 2003-11-28 | Medicine for treating hysteromyoma |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1255137C (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100391444C (en) * | 2005-12-29 | 2008-06-04 | 辽宁好护士药业（集团）有限责任公司 | Mammary aggregation elimination capsule and its preparation method |
| CN101966325A (en) * | 2010-10-28 | 2011-02-09 | 南京市中医院 | Medicament for treating damp-heat stasis blocking type endometriosis and preparation method thereof |
| CN102038799A (en) * | 2010-12-07 | 2011-05-04 | 哈尔滨泰华药业股份有限公司 | Application of breast lump-elimination preparation in preparing medicines for treating dysmenorrhea |
| CN103656431A (en) * | 2013-12-11 | 2014-03-26 | 山东中大药业有限公司 | Traditional Chinese medicine for treating hysteromyoma |
-
2003
- 2003-11-28 CN CNB200310105219XA patent/CN1255137C/en not_active Expired - Lifetime
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100391444C (en) * | 2005-12-29 | 2008-06-04 | 辽宁好护士药业（集团）有限责任公司 | Mammary aggregation elimination capsule and its preparation method |
| CN101966325A (en) * | 2010-10-28 | 2011-02-09 | 南京市中医院 | Medicament for treating damp-heat stasis blocking type endometriosis and preparation method thereof |
| CN101966325B (en) * | 2010-10-28 | 2011-11-16 | 南京市中医院 | Medicament for treating damp-heat stasis blocking type endometriosis and preparation method thereof |
| CN102038799A (en) * | 2010-12-07 | 2011-05-04 | 哈尔滨泰华药业股份有限公司 | Application of breast lump-elimination preparation in preparing medicines for treating dysmenorrhea |
| CN102038799B (en) * | 2010-12-07 | 2012-07-04 | 哈尔滨泰华药业股份有限公司 | Application of breast lump-elimination preparation in preparing medicines for treating dysmenorrhea |
| CN103656431A (en) * | 2013-12-11 | 2014-03-26 | 山东中大药业有限公司 | Traditional Chinese medicine for treating hysteromyoma |
| CN103656431B (en) * | 2013-12-11 | 2016-02-10 | 山东中大药业有限公司 | A kind of Chinese medicine for the treatment of hysteromyoma |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1255137C (en) | 2006-05-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102258658B (en) | Plaster for invigorating blood circulation and relieving pain | |
| CN110478452A (en) | A kind of Chinese medicine composition and preparation method thereof for treating gout | |
| CN103920034A (en) | Traditional Chinese medicine composition for alleviating side effects of chemotherapy of cancer patient and preparation method traditional Chinese medicine composition | |
| CN102872408B (en) | Chinese medicinal preparation treating dysmenorrhea | |
| CN1255137C (en) | Medicine for treating hysteromyoma | |
| CN102886019A (en) | Traditional Chinese medicinal blood sugar reducing plaster | |
| CN103920058A (en) | Traditional Chinese medicine preparation for treating headache and preparation method thereof | |
| CN103394002A (en) | Medicinal composition for treating cutaneous pruritus as well as preparation method and application thereof | |
| CN1517115A (en) | Chinese patent drug-Fuyan capsdule for treating chronic pelvic inflammation | |
| CN105535305A (en) | Chinese patent medicine for treating sequelae of cerebral infarction and preparation method thereof | |
| CN1324633A (en) | Hyperosteogeny-treating capsule | |
| CN103948694A (en) | Wind expelling and arthromyodynia dredging traditional Chinese medicine and preparation method thereof | |
| CN102961662B (en) | Medicine for treating gastric ulcer and preparation method thereof | |
| CN102973899B (en) | Traditional Chinese medicine composition for treating cholelithiasis | |
| CN1994415B (en) | Orally administered Chinese medicine for treating dysmenorrhea | |
| CN101129901A (en) | Traditional Chinese medicine composition for treating hysteromyoma | |
| CN101757379A (en) | Traditional Chinese medicine formula for treating female pelvic inflammation | |
| CN101066428A (en) | Medicine for treating sterility of aspermia and its prepn process | |
| CN104906256A (en) | Traditional Chinese medicine composition for treating gout | |
| CN104524157B (en) | A kind of Chinese medicine preparation for the treatment of goiter | |
| CN116650609A (en) | Kidney-reinforcing and embryo-culturing medicament and preparation method thereof | |
| CN115252679A (en) | Traditional Chinese medicine composition for treating ischemic cardiomyopathy and application thereof | |
| CN102406752A (en) | Traditional Chinese medicine composition for treating Bi syndromes | |
| CN1298350C (en) | Medicinal spirit for rheumatic arthritis | |
| CN103070998B (en) | Externally-applied plaster for curing pain of rheumatic joints |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C56 | Change in the name or address of the patentee |
Owner name: LIAONING HAOHUSHI PHARMACEUTICAL (GROUP) CO., LTD. Free format text: FORMER NAME: LIAONING HUANREN PHARMACEUTICAL CO., LTD. |
|
| CP01 | Change in the name or title of a patent holder |
Address after: 117201, Xin'an street, Huanren Town, Huanren Manchu Autonomous County, Benxi, Liaoning Patentee after: LIAONING GOOD NURSE PHARMACEUT Address before: 117201, Xin'an street, Huanren Town, Huanren Manchu Autonomous County, Benxi, Liaoning Patentee before: Liaoning Huanren Pharmaceutical Co.,Ltd. |
|
| C56 | Change in the name or address of the patentee | ||
| CP03 | Change of name, title or address |
Address after: 117000, No. 6, Taishan Road, five female mountain Economic Development Zone, Huanren County, Liaoning, Benxi Patentee after: LIAONING HERBPEX PHARMACEUTICAL (GROUP) CO.,LTD. Address before: 117201, Xin'an street, Huanren Town, Huanren Manchu Autonomous County, Benxi, Liaoning Patentee before: LIAONING GOOD NURSE PHARMACEUT |
|
| CX01 | Expiry of patent term |
Granted publication date: 20060510 |
|
| CX01 | Expiry of patent term |